Drug intelligence / Profile preview

TRN-006

Development stage: Preclinical
Lead developer: Turn Biotechnologies
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

TRN-006 is a preclinical mRNA therapeutic candidate reported as being developed by Turn Biotechnologies for wounds and injuries. Publicly available pipeline-database information identifies it as an mRNA program but does not disclose its encoded payload, molecular target, delivery system, route of administration, or specific mechanism of action. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/4d697866059842bea7517e477fba96f8))

Other names: TRN 006TRN006TRN-006

Beyond the preview

Go deeper on TRN-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRN-006.

Explore the full profile